3-Methoxyphencyclidine (also known as 3-MeO-PCP) is a lesser-known novel dissociative substance of the arylcyclohexylamine class. 3-MeO-PCP is a derivative of phencyclidine (PCP) and is chemically related to substances like methoxetamine and 3-MeO-PCE. It produces its effects by blocking NMDA receptors in the brain.

3-MeO-PCP was first synthesized in 1979 in an investigation of phencyclidine (PCP) derivatives. However, its activity in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle reported qualitative similarities to PCP along with comparable potency. In 2009, it began to be discussed on online forums such as bluelight.ru and was made available for sale on the research chemicals market.

Like other arylcyclohexlyamines, 3-MeO-PCP induces a state referred to as “dissociative anesthesia”, although the extent to which this occurs is reported to be highly dose-dependent and variable in its effects. It is commonly taken orally and nasally, although it may also be smoked and injected. It has been noted for its subtle come up and tendency to produce delusions of sobriety, which can lead to compulsive redosing.

Very little data exists for the pharmacology, metabolism, and toxicity of 3-MeO-PCP. Due to its potent hallucinogenic effects and lack of research, it is strongly advised to use use harm reduction practices if using this substance.

Showing the single result

10unce

3-MeO-PCP